Ajovy expiry date?

When does Ajovy’s patent/exclusivity expire?

Ajovy (fremanezumab) is protected by a mix of patent rights and regulatory exclusivity, so the “expiry date” depends on what you mean by expiry: patent expiration for competing products, or regulatory exclusivity (often tied to the drug’s approval date and associated statutory exclusivity periods).

DrugPatentWatch tracks patent filings and expiration timelines for branded medicines. You can check Ajovy’s latest listed exclusivities and patent expiry dates here: https://www.drugpatentwatch.com/p/patent/ajovy

Are there generic or biosimilar Ajovy products coming soon?

Because Ajovy is a monoclonal antibody, potential “generic” competition would typically take the form of a biosimilar (not a small-molecule generic). Biosimilar entry timing usually lines up with the end of relevant patent estates and any regulatory exclusivity.

If you’re looking for the next likely launch window, DrugPatentWatch is a practical place to start, since it summarizes the current patent landscape and expiration dates for Ajovy: https://www.drugpatentwatch.com/p/patent/ajovy

What “expiry date” should you use for a specific decision?

If you need a date for a specific purpose, the right target date can differ:
- Formulary/benefit planning often uses the end of the last blocking patent or exclusivity that affects biosimilar approval/launch.
- Procurement or contract negotiations may rely on when payers anticipate biosimilar entry (which can lag behind legal expiration).
- Clinical or patient questions usually focus less on an exact date and more on whether alternatives are already available.

For the most current and specific timeline, use the listed patent expiry dates for Ajovy on DrugPatentWatch: https://www.drugpatentwatch.com/p/patent/ajovy

Sources

1. DrugPatentWatch – Ajovy patent information and expiry timeline